<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00323791</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000539400</org_study_id>
    <secondary_id>P30CA072720</secondary_id>
    <secondary_id>CINJ-080507</secondary_id>
    <secondary_id>CINJ-5633</secondary_id>
    <secondary_id>CINJ-NJ3805</secondary_id>
    <nct_id>NCT00323791</nct_id>
  </id_info>
  <brief_title>Gemcitabine With or Without Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer</brief_title>
  <official_title>A Phase II Trial of Gemzar (Gemcitabine) and Gleevec (Imatinib Mesylate) in Patients With Metastatic Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Medicine and Dentistry of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Rutgers, The State University of New Jersey</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop&#xD;
      the growth of tumor cells, either by killing the cells or by stopping them from dividing.&#xD;
      Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed&#xD;
      for cell growth. Giving gemcitabine together with imatinib mesylate may kill more tumor&#xD;
      cells.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying gemcitabine and imatinib mesylate to see&#xD;
      how well they work compared with gemcitabine alone in treating patients with metastatic or&#xD;
      unresectable kidney cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare stable disease and objective response in patients with metastatic or&#xD;
           unresectable renal cell carcinoma treated with gemcitabine hydrochloride with or without&#xD;
           imatinib mesylate.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Evaluate the median survival, progression-free survival, and response rate in patients&#xD;
           treated with gemcitabine hydrochloride and imatinib mesylate.&#xD;
&#xD;
        -  Determine the qualitative and quantitative toxic effects of this regimen in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine the expression of c-KIT and platelet-derived growth factor receptor-alpha&#xD;
           protein expression in both tumor cells and associated endothelial cells using&#xD;
           immunohistochemistry staining of paraffin-embedded tissue.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified by histology (clear&#xD;
      cell vs nonclear cell) and prior therapy (immunotherapy/chemotherapy vs targeted agents).&#xD;
&#xD;
      Patients receive gemcitabine hydrochloride IV on days 3 and 10 and oral imatinib mesylate on&#xD;
      days 1-5 and 8-12. Treatment repeats every 21 days for up to 2 courses in the absence of&#xD;
      disease progression or unacceptable toxicity. Patients achieving partial or complete response&#xD;
      after 2 courses of treatment continue treatment with gemcitabine hydrochloride and imatinib&#xD;
      mesylate in the absence of disease progression or unacceptable toxicity. Patients with stable&#xD;
      disease after 2 courses of treatment are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive gemcitabine hydrochloride IV on days 3 and 10.&#xD;
&#xD;
        -  Arm II: Patients receive gemcitabine hydrochloride IV on days 3 and 10 and oral imatinib&#xD;
           mesylate on days 1-5 and 8-12.&#xD;
&#xD;
      In both arms, treatment repeats every 21 days for at least 3 courses in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      Available archived tumor tissue samples are obtained for immunohistochemical analysis to&#xD;
      quantify the expression of c-KIT and platelet-derived growth factor receptor-alpha protein&#xD;
      expression.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 100 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow accrual&#xD;
  </why_stopped>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Stable disease</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expression of c-KIT and platelet-derived growth factor receptor-alpha protein expression</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Kidney Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib mesylate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>protein expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed renal cell carcinoma&#xD;
&#xD;
               -  Metastatic disease OR unresectable primary tumor&#xD;
&#xD;
               -  No known curative therapy exists&#xD;
&#xD;
          -  Documented progressive renal cell carcinoma as defined by RECIST criteria within the&#xD;
             past 6 months&#xD;
&#xD;
          -  Measurable disease with ≥ 1 unidimensionally measurable lesion&#xD;
&#xD;
          -  No known symptomatic brain metastasis or untreated brain metastases or carcinomatous&#xD;
             meningitis&#xD;
&#xD;
               -  Treated brain metastasis allowed provided the following criteria are met:&#xD;
&#xD;
                    -  Clinically stable&#xD;
&#xD;
                    -  More than 7 days since prior steroids&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times ULN&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN OR creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective nonhormonal contraception during and for 3 months&#xD;
             after completion of study treatment&#xD;
&#xD;
          -  Must be able to swallow oral medication&#xD;
&#xD;
          -  No coexisting medical condition that would preclude study compliance&#xD;
&#xD;
          -  No history of allergic reaction to compounds of similar chemical or biological&#xD;
             composition to gemcitabine hydrochloride and/or imatinib mesylate&#xD;
&#xD;
          -  No uncontrolled illness that would preclude study participation&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia requiring therapy&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No other malignancy within the past 5 years except carcinoma in situ of the cervix or&#xD;
             nonmelanoma skin cancer&#xD;
&#xD;
          -  No New York Heart Association class III-IV congestive heart failure&#xD;
&#xD;
          -  No known chronic liver disease (i.e., chronic active hepatitis or cirrhosis)&#xD;
&#xD;
          -  No known HIV positivity&#xD;
&#xD;
          -  No significant history of noncompliance to medical regimens&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
&#xD;
          -  No more than 3 prior treatment regimens, including any of the following:&#xD;
&#xD;
               -  No more than 1 prior cytotoxic therapy&#xD;
&#xD;
               -  Immunotherapy regimens comprising interferon and/or aldesleukin&#xD;
&#xD;
               -  Therapy with molecular targets&#xD;
&#xD;
               -  Any combination of the above treatments to a maximum of 3 total therapies&#xD;
&#xD;
          -  No prior gemcitabine hydrochloride for metastatic disease&#xD;
&#xD;
          -  No prior imatinib mesylate for metastatic disease&#xD;
&#xD;
          -  More than 2 weeks since prior major surgery&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas)&#xD;
&#xD;
          -  At least 3 weeks since prior anti-vascular endothelial growth factor therapy&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy&#xD;
&#xD;
               -  Must have evidence of ≥ 1 measurable target lesion outside the radiation fields&#xD;
                  OR radiologically confirmed disease progression within the radiation fields after&#xD;
                  completion of radiotherapy&#xD;
&#xD;
          -  At least 28 days since prior and no other concurrent investigational or commercial&#xD;
             agents, unless disease is rapidly progressing&#xD;
&#xD;
          -  No concurrent therapeutic warfarin&#xD;
&#xD;
               -  Concurrent low molecular weight heparin or heparin allowed for therapeutic&#xD;
                  anticoagulation&#xD;
&#xD;
               -  Concurrent prophylactic warfarin therapy ≤ 1 mg daily to maintain catheter&#xD;
                  patency allowed&#xD;
&#xD;
          -  No concurrent filgrastim (G-CSF) for prevention of neutropenia&#xD;
&#xD;
          -  No other concurrent chemotherapy, immunotherapy, hormonal cancer therapy, radiation&#xD;
             therapy, or cancer surgery&#xD;
&#xD;
          -  No concurrent routine use (i.e., daily or every other day) of systemic corticosteroid&#xD;
             therapy (in supraphysiologic doses)&#xD;
&#xD;
          -  No concurrent medication that would preclude study compliance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Stein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers Cancer Institute of New Jersey</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <study_first_submitted>May 8, 2006</study_first_submitted>
  <study_first_submitted_qc>May 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2006</study_first_posted>
  <last_update_submitted>December 10, 2009</last_update_submitted>
  <last_update_submitted_qc>December 10, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2009</last_update_posted>
  <responsible_party>
    <name_title>Mark Stein, MD</name_title>
    <organization>UMDNJ/CINJ</organization>
  </responsible_party>
  <keyword>recurrent renal cell cancer</keyword>
  <keyword>clear cell renal cell carcinoma</keyword>
  <keyword>papillary renal cell carcinoma</keyword>
  <keyword>stage IV renal cell cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

